[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362946-105":59,"doc-detail-362946-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-epigenetic-networks-to-overcome-cisplatin-resistance-in-ovarian-cancer-from-mechanisms-to-clinical-translation","Targeting epigenetic networks to overcome cisplatin resistance in ovarian cancer - from mechanisms to clinical translation","","Platinum-resistant ovarian cancer carries a poor five-year survival rate of about 30% due to limited effectiveness of current therapies. This review addresses a gap in understanding resistance mechanisms and their clinical translation, moving beyond studies of single epigenetic alterations. It integrates evidence into an “Epigenetic Resistance Stability Network” model with four foundational epigenetic layers, three interacting epigenetic networks, and a framework including compensation and temporal regulation. A translational roadmap covers biomarker validation, combination therapy development, and personalized intervention to improve outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-epigenetic-networks-to-overcome-cisplatin-resistance-in-ovarian-cancer-from-mechanisms-to-clinical-translation/362946/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-epigenetic-networks-to-overcome-cisplatin-resistance-in-ovarian-cancer-from-mechanisms-to-clinical-translation/362946.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is platinum resistance in ovarian cancer clinically challenging?","Question",{"text":112,"@type":113},"Platinum-resistant patients have a poor five-year survival rate (~30%) because current therapies show limited effectiveness, with most patients experiencing recurrence soon after treatment. The lack of precise biomarkers and insufficient combination strategies further complicate management.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the core model proposed in the review?",{"text":117,"@type":113},"The review proposes an “Epigenetic Resistance Stability Network” model integrating three elements: four foundational epigenetic layers, three interactive epigenetic networks that sustain the resistant phenotype, and a theoretical framework covering compensation and temporal progression of resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review translate the model into clinical directions?",{"text":121,"@type":113},"It outlines a translational roadmap focusing on biomarker validation (e.g., SFRP5 methylation and circITGB6), development of combination therapies, and personalized intervention strategies to overcome cisplatin resistance and improve patient outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362946,1790387425,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Tang et al. Journal of Ovarian Research (2026) 19:135  \n[https://doi.org/10.1186/s13048-026-02005-0](https://doi.org/10.1186/s13048-026-02005-0)  \nJournal of Ovarian Research  \nREVIEW Open Access  \nTargeting epigenetic networks to overcome cisplatin resistance in ovarian cancer:  \nfrom mechanisms to clinical translation  \nMaoyan Tang1, Yu Wang1, Yaya Xie1, Jia Li2, Danni Ding2, Chan Li1, Qiaochu Chen1 and Fengjuan Han2*  \nAbstract  \nOvarian cancer patients with platinum resistance face a dismal five-year survival rate of only 30%, owing to the limited efficacy of current therapeutic options. Existing research often focuses on individual epigenetic modifications, which hampers a systematic understanding of resistance mechanisms and their clinical translation. To address this, our review integrates current evidence to propose an “Epigenetic Resistance Stability Network”model, which comprises three core components: (i) four foundational layers, each with distinct roles in cisplatin resistance. These include DNA methylation (e. g., SFRP5 hypermethylation activating the Wnt pathway), non-coding RNAs (ncRNAs), RNA modifications, and histone modifications, which govern gene expression, post-transcriptional regulation, RNA function, and chromatin architecture, respectively. (ii) three interactive networks: “DNA methylation/ miRNA feedback loops,” “lncRNA/histone modification cascades,” and “circRNA/m6A synergistic stabilization.” These networks sustain the resistant phenotype by interlinking key nodes across the four foundational layers. (iii) a theoretical framework encompassing two parts: the “Epigenetic Compensation Network” theory (explaining how tumors evade single-target therapies) and the “Epigenetic Temporal Regulation” model (outlining resistance progression: “miRNA response → methylation consolidation → chromatin stabilization”) . Building on this model, we outline a translational roadmap involving “biomarker validation (e. g., SFRP5 methylation, circITGB6),” “combination therapy development,” and “personalized intervention,” offering novel insights for overcoming cisplatin resistance and improving patient outcomes in ovarian cancer.  \nIntroduction  \nOvarian cancer is one of the three most common gynecological malignant tumors, with high-grade serous ovarian cancer (HGSC) being the most common subtype. Globally, there are approximately 1.314 million new cases of ovarian cancer each year, resulting in 207,000 deaths annually, making it the leading cause of death  \n*Correspondence:  \nFengjuan Han  \n[hanfengjuan2004@163.com](hanfengjuan2004@163.com)  \n1Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China 2Department of Obstetrics and Gynecology, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China  \namong gynecological malignant tumors [1]. The current first-line treatment regimen consists of cytoreductive surgery combined with platinum-based chemotherapy [2], cisplatin (cis-[PtCl₂(NH₃)₂]) inhibits transcription and replication by forming DNA adducts and induces apoptosis [3]; however, approximately 85% of patients with epithelial ovarian cancer experience recurrence within six months of treatment (a condition defined as“cisplatin resistance”) [4, 5]. Although novel therapeutic strategies and targeted therapies, including intraperitoneal administration, poly (ADP-ribose) polymerase (PARP) inhibitors, and anti-angiogenic agents, have been introduced, the five-year survival rate for patients  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this l","cbCaivbWgMpsUv8V","https://ap.wps.com/l/cbCaivbWgMpsUv8V","pdf",11444473,29,"English","# Abstract\n# Introduction","[{\"question\":\"Why is platinum resistance in ovarian cancer clinically challenging?\",\"answer\":\"Platinum-resistant patients have a poor five-year survival rate (~30%) because current therapies show limited effectiveness, with most patients experiencing recurrence soon after treatment. The lack of precise biomarkers and insufficient combination strategies further complicate management.\"},{\"question\":\"What is the core model proposed in the review?\",\"answer\":\"The review proposes an “Epigenetic Resistance Stability Network” model integrating three elements: four foundational epigenetic layers, three interactive epigenetic networks that sustain the resistant phenotype, and a theoretical framework covering compensation and temporal progression of resistance.\"},{\"question\":\"How does the review translate the model into clinical directions?\",\"answer\":\"It outlines a translational roadmap focusing on biomarker validation (e.g., SFRP5 methylation and circITGB6), development of combination therapies, and personalized intervention strategies to overcome cisplatin resistance and improve patient outcomes.\"}]","Targeting epigenetic networks to overcome cisplatin resistance in ovarian cancer - from mechanisms to clinical translation | PDF",1790149506,73,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebf871475a202e52125d0344f930a1fd.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/209b681de4353a91821ab073fe7f54e8.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4e4af84935a408eadb79aa55ffde06b.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2eb1d411e92792f416877f33a278f5ca.webp",980,1306]